GlassScriptPhysician profile
Olena Ivanova
NPI 1588253611
$718.75
in general payments reported to CMS, 2019-2025
13 companies · $22.92 in 2025
The $22.92 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $189 · 2023: $275 · 2024: $92.78 · 2025: $22.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $245.40 | 2021-2024 | |
| Novo Nordisk INC | $100.84 | 2022-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $97.90 | 2021-2024 | |
| Daiichi Sankyo INC. | $86.10 | 2021-2022 | |
| Lilly USA, LLC | $45.25 | 2022-2023 | Jardiance, Emgality |
| Exact Sciences Corporation | $24.86 | 2023 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.92 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.82 | 2022 | |
| Merck Sharp & Dohme LLC | $19.41 | 2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Amgen INC. | $15.70 | 2023 | Otezla, Repatha |
| Dynavax Technologies Corporation | $14.94 | 2023 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $13.11 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olena Ivanova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.